Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kendra Sweet

Showing results (1-10 of 82) with videos related to

Pageof 9
Sort By:
Current Opinion in Hematology|January 24, 2020
Blastic plasmacytoid dendritic cell neoplasm: diagnosis, manifestations, and treatmentKendra Sweet
Journal of the National Comprehensive Cancer Network : JNCCN|May 8, 2023
Blastic Plasmacytoid Dendritic Cell NeoplasmAkriti Jain, Kendra Sweet
British Journal of Haematology|December 2, 2024
Clinical perspectives on post-induction maintenance therapy in patients with acute myeloid leukaemia in remission who are ineligible for allogeneic haematopoietic stem cell transplantationKendra Sweet, Thomas Cluzeau
Current Hematologic Malignancy Reports|October 7, 2021
Treatment-Free Remission: the New Goal in CML TherapyEhab Atallah, Kendra Sweet
Leukemia Research|September 18, 2018
Recently approved therapies in acute myeloid leukemia: A complex treatment landscapeChetasi Talati, Kendra Sweet
Clinical Lymphoma, Myeloma & Leukemia|November 8, 2017
State of the Art Update and Next Questions: Acute Myeloid LeukemiaKendra Sweet, Jeffrey Lancet
Hematology. American Society of Hematology. Education Program|December 10, 2013
Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: when is this a safe option to consider?Kendra Sweet, Vivian Oehler
Critical Reviews in Oncology/Hematology|June 6, 2016
Early switch in tyrosine kinase inhibitor therapy for patients with chronic myeloid leukemia: An emerging clinical questionKendra Sweet, Javier Pinilla-Ibarz
Best Practice & Research. Clinical Haematology|November 15, 2016
NCCN and ELN: What do the guidelines tell us?Kendra Sweet, Javier Pinilla-Ibarz
Current Hematologic Malignancy Reports|March 18, 2014
Novel therapeutics in acute myeloid leukemiaKendra Sweet, Jeffrey E Lancet
Pageof 9

Showing results (1-10 of 82) with videos related to

Sort By:
Pageof 9
Current Opinion in Hematology|January 24, 2020
Blastic plasmacytoid dendritic cell neoplasm: diagnosis, manifestations, and treatmentKendra Sweet
Journal of the National Comprehensive Cancer Network : JNCCN|May 8, 2023
Blastic Plasmacytoid Dendritic Cell NeoplasmAkriti Jain, Kendra Sweet
British Journal of Haematology|December 2, 2024
Clinical perspectives on post-induction maintenance therapy in patients with acute myeloid leukaemia in remission who are ineligible for allogeneic haematopoietic stem cell transplantationKendra Sweet, Thomas Cluzeau
Current Hematologic Malignancy Reports|October 7, 2021
Treatment-Free Remission: the New Goal in CML TherapyEhab Atallah, Kendra Sweet
Leukemia Research|September 18, 2018
Recently approved therapies in acute myeloid leukemia: A complex treatment landscapeChetasi Talati, Kendra Sweet
Clinical Lymphoma, Myeloma & Leukemia|November 8, 2017
State of the Art Update and Next Questions: Acute Myeloid LeukemiaKendra Sweet, Jeffrey Lancet
Hematology. American Society of Hematology. Education Program|December 10, 2013
Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: when is this a safe option to consider?Kendra Sweet, Vivian Oehler
Critical Reviews in Oncology/Hematology|June 6, 2016
Early switch in tyrosine kinase inhibitor therapy for patients with chronic myeloid leukemia: An emerging clinical questionKendra Sweet, Javier Pinilla-Ibarz
Best Practice & Research. Clinical Haematology|November 15, 2016
NCCN and ELN: What do the guidelines tell us?Kendra Sweet, Javier Pinilla-Ibarz
Current Hematologic Malignancy Reports|March 18, 2014
Novel therapeutics in acute myeloid leukemiaKendra Sweet, Jeffrey E Lancet
Pageof 9